# Arkansas Cannabis Laws Explained (2026) | Medical Marijuana, Possession & DUI Laws > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/arkansas-cannabis-laws-explained-2026-medical-marijuana-possession-dui-laws/ > **Published:** 2026-06-22T07:24:09-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:50:58-04:00 > **Clinical Summary:** Arkansas medical cannabis legal requirements 2026: qualifying conditions, physician certification, DUI standards, and possession limits for clinical practice. --- ✦ New CED Clinical Relevance #47 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyPainAnxietyMental HealthSafetyHempTHC Why This Matters Clinicians in Arkansas need to understand the 2026 [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) legal framework to properly counsel patients on qualifying conditions, safe prescribing practices, and potential drug interactions with other medications. Clear knowledge of state possession limits and DUI laws allows providers to educate patients on legal risks and responsible use, particularly regarding impaired driving. This information ensures clinicians can integrate cannabis into treatment plans within legal boundaries while protecting patient safety and avoiding liability. Clinical Summary Arkansas maintains a regulated [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) program with specific qualifying conditions that clinicians should understand when counseling patients about legal treatment options. The state’s [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) framework establishes clear guidelines for patient eligibility, licensing requirements, and legal possession limits that directly impact prescribing practices and patient access to cannabis as a therapeutic agent. Understanding Arkansas’s DUI laws and impairment standards is critical for clinicians advising patients about safe use, driving restrictions, and potential legal consequences of cannabis consumption. The distinction between medical authorization and legal protection varies in Arkansas, meaning patients with valid medical cards still face specific limitations on where and how they can use cannabis, even for therapeutic purposes. Clinicians should be familiar with the current qualifying conditions list, as these determine which patients can legally access [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) and may influence treatment recommendations for eligible individuals. For clinical practice in Arkansas, staying current with the 2026 updates to [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) laws ensures that clinicians can accurately counsel patients on legal options, restrictions, and the implications of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) for their specific medical conditions. Dr. Caplan’s Take “Arkansas has established a regulated [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) program with defined qualifying conditions, which gives us a legal framework to work within, but I’d emphasize that our clinical evidence base for cannabis remains limited and condition-specific. As practitioners, we need to stay current on both the legal landscape and the actual peer-reviewed data supporting use in each patient’s particular condition, rather than assuming legalization equals clinical endorsement.” Clinical Perspective 🏥 Arkansas’s medical marijuana program represents one regulatory approach to cannabis access, but clinicians should recognize that state legalization does not resolve fundamental uncertainties about [cannabis safety](https://cedclinic.com/respiratory-effects-inhalational-marijuana/), efficacy, or optimal dosing for specific conditions. The expansion of legal medical cannabis in Arkansas may increase patient inquiries about therapeutic use, yet evidence for most indications remains limited, and providers cannot rely on state approval as validation of clinical benefit. Importantly, clinicians should remain cautious about potential drug interactions, impaired driving risk (particularly relevant given DUI law discussions), and the variable cannabinoid profiles across products, which may not be equivalent across jurisdictions or suppliers. Given these gaps, healthcare providers in Arkansas should consider developing a systematic approach to cannabis counseling that acknowledges patient access while maintaining skepticism about unproven claims, documenting discussions clearly, and encouraging patients to report actual outcomes to inform ongoing treatment decisions. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Arkansas%20Cannabis%20Laws%20Explained%20%282026%29%20%7C%20Medical%20Marijuana%2C%20Possession%20%26amp%3B%20DUI%20Laws%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D63929)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D63929)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Arkansas%20Cannabis%20Laws%20Explained%20%282026%29%20%7C%20Medical%20Marijuana%2C%20Possession%20%26amp%3B%20DUI%20Laws%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D63929)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 405 Items — March 12, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-2026-spring-launch/) - [CED Digest: 392 Items — March 11, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) 📰 Source: [https://www.youtube.com/watch?v=XHFuowRW-_g](https://www.youtube.com/watch?v=XHFuowRW-_g) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).